ODAC to review Amgen’s Nplate, ESAs
Executive Summary
FDA's Oncologic Drugs Advisory Committee will meet March 12-13 to review the cumulative data, including recent study results, on the risk of erythropoeisis-stimulating agents in patients with cancer and to consider the BLA for Amgen's platelet producer Nplate (romiplostim). Discussion regarding the safety of ESAs will focus on Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit as well as Roche's Mircera, FDA says in the Jan. 25 Federal Register. At the last ODAC review of ESA safety, the panel recommended that sponsors conduct additional trials to support continued marketing in the oncology setting (1"The Pink Sheet" May 14, 2007, p. 3)...
You may also be interested in...
EPO Scathed But Survives ODAC Challenge; Cmte. Calls For Additional Trials
Sponsors of erythropoiesis-stimulating agents should conduct additional safety studies to support continued marketing in the oncology setting, FDA's Oncologic Drugs Advisory Committee unanimously recommends
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.